Search

Displaying results 1441 - 1450 of 8171 in total
  1. Drug

    PF-06260414

    go.drugbank.com/drugs/DB15221
    Investigational

    PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

  2. Drug

    PF-232798

    go.drugbank.com/drugs/DB14813
    Investigational

    PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).

    Synonyms: PF-00232798
  3. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [A249320] The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as [rituximab], in combination with chemotherapy. … [L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells.

  4. Drug

    Silicon

    go.drugbank.com/drugs/DB12982
    Approved

    Silicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).

    Mixtures: Calcium With Mg Zn Mn Cu CR Si and Vit. C & D, Active Calcium Plus Magnesium, Vitamin D and Silicon
  5. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. … Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B.

  6. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Van-letrozole
  7. Drug

    Technetium Tc-99m exametazime

    go.drugbank.com/drugs/DB09163
    Approved

    It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease.

  8. Drug

    Antrafenine

    go.drugbank.com/drugs/DB01419
    Approved

    Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen.

  9. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  10. Drug

    Lerodalcibep

    go.drugbank.com/drugs/DB19071
    ApprovedInvestigational

    [L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia